Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 3Myeloproliferative Disorders 2Leukemia, Monocytic, Acute 2Thrombocythemia, Essential 1Rectal Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

fludarabine phosphate 87Cyclophosphamide 78Whole-Body Irradiation 59Azacitidine 59fludarabine 56Mycophenolic Acid 56Busulfan 53Tacrolimus 51Peripheral Blood Stem Cell Transplantation 41Melphalan 40Cytarabine 38Antilymphocyte Serum 38Filgrastim 37Granulocyte Colony-Stimulating Factor 33Cyclosporine 33Methotrexate 32Decitabine 32thymoglobulin 22Thiotepa 21Clofarabine 21Cord Blood Stem Cell Transplantation 19Stem Cell Transplantation 16Alemtuzumab 16Sirolimus 15Rituximab 15sargramostim 12Lenalidomide 12Etoposide 11Radiotherapy 10Cyclosporins 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Myelodysplastic Syndromes × Liposomes × Clear all
NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

National Cancer Institute (NCI)

Phase 2 Active not recruiting
50 enrolled 12 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡